The E100: Extending runways, dumping drugs, factoring in a banking crisis and grappling with the IRA — there's a lot for biotech execs to deal with
If there’s one major theme playing out in biotech this year, it’s watching out for the pitfalls. And then getting hit out of left field by something new and unexpected.
For our H1 survey, I wanted to gauge the temperature of a large group of biotech executives — largely CEOs — as they weather the storm following two years of blue skies and clear sailing. And their concerns — counted among 77 execs who took part — came through loud and clear.
This article is for premium subscribers only
Upgrade to a premium subscription plan for unlimited access, and join our community of key biopharma players.